drugset / Trial / NCT04382846

Novel Regimens in COVID-19 Treatment

NCT04382846

Phase 3 Recruiting 160 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Timeline

Start
2020-05-08
Primary completion
2030-12-01
Completion
2030-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified

Indications